The use of solvent/detergent mixtures and various forms of heat treatment t o inactivate viruses has become widespread in the preparation of blood derivatives. Because viruses that lack lipid envelopes and/or are heat resistant, eg, hepatitis A virus (HAV) or parvovirus B19 may be present, the use of two methods of virus elimination that operate by different mechanisms has been advocated. We now report on short wavelength ultraviolet light (UVC) irradiation for virus inactivation and enhancement of its compatibility with proteins by quenchers of reactive oxygen species (ROS). Treatment of an antihemophilic factor (AHF) concentrate or whole plasma with 0.1 J/cm2 inactivated 10' t o 2 10' infectious doses (ID) of encephalomyocarditis virus (EMCV), HAV, bacteriophage M13, vesicular stomatitis virus (VSV), and porcine parvovirus. However, the recovery of factor Vlll was 30% or lower HE VIRAL SAFETY of coagulation factor concentrates and other blood derivatives has been enhanced significantly over the past 10 to 15 years as a consequence of improvements in donor screening and, most importantly, implementation of virucidal procedures shown not to damage protein^.'.'.^ Prevalent virucidal procedures today use solvenvdetergent mixtures that act to disrupt the envelope of lipid enveloped viruses or heat treatment of solute-stabilized or lyophilized preparations at 60" to 100°C. Enhanced viral safety with respect to human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) has been confirmed in prospective closely monitored clinical trials. Nonetheless, principally as a consequence of several outbreaks of hepatitis A among the attention given by the transfusion community to these outbreaks8 and the continued transmission of parvovirus B 19: " the development of new virucidal procedures directed against nonenveloped and heat stable viruses has been advocated.
We now report our experience in treating an antihemophilic factor (AHF) concentrate and whole plasma with short wavelength ultraviolet light (UVC) in the presence of quenchers of radicals and reactive oxygen species (ROS). UVC was selected because it inherently targets nucleic acids rather than proteins due to the much higher extinction coefficient of the former at 260 nm and their larger target size. As a result, UVC can inactivate a wide variety of viruses, especially single stranded viruses."." Moreover, our experience in the virucidal treatment of cellular blood products with light activated compounds indicated that protein and cellular damage induced by irradiation could be largely eliminated without adversely affecting virus kill by antioxidant inclusion.'3"s on treatment of an AHF concentrate and 6 0 % on treatment of plasma. Factor Vlll recovery could be increased with little or no effect on virus kill by addition of rutin, a flavonoid known t o quench both type I and type II ROS. On treatment of plasma in the presence of rutin, the recovery of several other coagulation factors was also enhanced by rutin addition and typically exceeded 75%. Electrophoretic analysis of treated AHF concentrate confirmed the advantage of rutin presence; UVC irradiation of plasma did not cause discernible changes in electrophoretic banding patterns, even in the absence of rutin. We conclude that addition of UVC treatment t o existing processes used in the manufacture of blood derivatives will provide an added margin of safety, especially for nonenveloped or heat-stable viruses. 0 1995 by The American Society of Hematology.
T MATERIALS AND METHODS

Reagents
the solveddetergent method and purified by ion exchange chromatography by the manufacturer to a specific activity of approximately 100 U/mg protein and is vialed at 100 U/mL. It was used without further purification.
Virus inactivation. Before irradiation, the indicated virus and quencher were added to the protein solution under study, after which the mixture was pumped peristaltically through a flat quartz cell (1 5 cm X 1.2 cm X 0.22 mm internal dimensions, 0.4 mL volume). The mixtures were irradiated using a low pressure mercury lamp (General Electric No. BLEITl55; Spectronics Corp, Westbury NY) emitting 90% of its energy at 254 nm. Irradiance was measured with a Spectroline DM-254H Digital Radiometer (Spectronics Corp), and total radiant energy was controlled by pump rate. A fluence of 0.1 J/cmZ corresponded to a pump rate of 2 mL/min and an exposure time of approximately 12 seconds.
Viruses and viral assays. Studies on the inactivation of vesicular stomatitis virus (VSV), encephalomyocarditis virus (EMCV), and hepatitis A virus (HAV) were performed as described previously.'"'R For VSV and EMCV, we assessed infectivity by endpoint, 10-fold serial dilutions using each dilution to inoculate eight replicate wells containing Vero cells (American Type Culture Collection, Rockville, MD) in 96-well microtiter plates. Virus-induced cytopathology was scored after 72 hours of incubation at 37°C in 5% CO2. Viral titer, calculated by the Spearman-Karber method," indicates the quantity of virus that infects 50% of the tissue culture wells. between IO' and IO6 in Dulbecco's modified Eagle's medium (DMEM; GIBCO Laboratories, Grand Island, NY) containing 5% fetal bovine serum (FBS; BioWhittaker, Walkersville, MD). Each dilution was tested in singlet for infectious virus by inoculating BS-C-I cells in petri dishes with 0.25 mL of the sample, incubating for 2 hours, after which the cells were overlayed with 0.5% agarose containing DMEM and 2% FBS. After culturing at 37°C in 5% COz for 6 days, the overlay was removed, the cells were fixed with acetone for 10 minutes, and reacted with IZ5I-anti-HAV antibody (HAVAB kit, Abbott Laboratories, Chicago, IL) diluted 20-fold with phosphate-buffered saline (PBS) containing 10% FBS at 37°C for 4 hours. Excess antibody was removed by washing three times with PBS containing 0.02% sodium azide, and the foci visualized by radioautography on Kodak Scientific Imaging Film X-OMAT AR (Kodak, Rochester, NY). Porcine parvovirus and parvovirus infectivity assays were provided by one of us (E.D.). Ten-fold serial dilutions (0.05 mL) of treated samples were added to an established line of swine testicle cells in 16-well Lab Tek plates with each dilution inoculated into eight wells. The inoculum was allowed to adsorb for 2 hours and was then removed and medium added. After a 3-to 4-day incubation at 37"C, the cells were washed, fixed in acetone, and stained for the presence of porcine parvovirus with a monoclonal antiparvovirus antibody as the primary antibody and fluorescein-conjugated, goat antimouse antibody as the secondary antibody. Additionally, to enhance test sensitivity, the remainder of the sample (about 1 mL) was also evaluated by addition to swine testicle cells in a T-25 flask. Virus was permitted to adsorb to the cell monolayer for I to 2 hours. after which medium was added, and the incubation continued at 37°C for S days. The monolayer was washed, the cells trypsinized, and then added to Lab Tek 16-well plates. After 2 to 3 days incubation, the cells were fixed and stained for porcine parvovirus as described above.
Bacteriophage M13 infectivity was measured by plaque assay on host Escherichia coli JMlOl cells."
Coagulationfactor assays. Samples for coagulation factor determination were either assayed immediately or frozen at -80°C. Each sample was assayed in duplicate and the results averaged. Duplicates were within 15% of each other. Coagulation factor activity for factor VIII, factor IX, factor X, and factor XI was determined by one-stage activated partial thromboplastin (APTT) time clotting assay, which measures the degree of correction of the clotting time of factordeficient plasma (George King Biomedical, Overland Park, KS) in Electrophoresis. Native and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were performed using 8 cm X 8 cm X 1.5 mm precast 4% to 12% gradient gels for plasma and 6% gels for AHF concentrates (Novex, San Diego, CA). The gels were run with Tris-glycine native buffer or Tris-glycine-SDS running buffer (Novex) on the Novex Xcell Mini-Cell at 125 V for 120 minutes. Staining was with Coomassie Brilliant Blue (BioRad Laboratories, Melville, NY).
RESULTS
Treatment of an AHF concentrate. The inactivation of phage M13 and the recovery of factor VIII coagulant activity with varying doses of W C were determined. Viral infectivity and factor VIII activity declined in parallel such that factor VIII recovery was only 30% at a UVC dose that inactivated 10' plaque forming units (PFU) of M13 (Fig 1) . Factor V m loss was not related to an increase in temperature, which was less than 1"C, or to the pumping of samples through the irradiator (data not shown). Factor VIU activity was substantially higher on inclusion of 0.5 mmoyL rutin before UVC treatment (Fig 2) . Rutin, a flavonoid, was selected because it is known to quench both type I and type II ROS and because of its protection of platelets against damage on treatment with psoralen and UVA.I4 Separate experiments established that the rutin effect was optimum at concentrations between 0.5 and 1 mmoVL (data not shown). In contrast, 0.5 mmoVL rutin had, at most, a minor effect on the inactivation of EMCV, a nonenveloped, single stranded RNA virus which serves as a model for HAV (Fig 3, left panel) , HAV (Fig 3, right panel) , VSV, a commonly employed model lipid enveloped virus (Fig 4, left  panel) or porcine parvovirus (Fig 4, right panel) . With respect to HAV and parvovirus, exposure of an AHF concentrate to 0.1 J/cmz UVC in the presence of 0.5 mmovL rutin inactivated EMCV tious doses (ID) of porcine parvovirus. On culturing l mL instead of 0.05 mL for parvovirus infectivity, the sample exposed to 0.090 J/cm2 W C was not infectious, consistent with the inactivation of 2 16." IDso of porcine parvovirus, whereas the sample exposed to 0.068 J/cm2 W C was positive, indicating the inactivation of 2 lo3.', but < Id IDso at this fluency.
Quenchers other than rutin were also evaluated. Factor VI11 recovery was significantly lower on substitution of rutin with 10 m m o K mannitol or 2 mmoVL glutathione (known to principally quench type I ROS), 2 mmoVL histidine or tryptophan (known to quench principally type I1 ROS), or a mixture of 10 mmol/L mannitol and 2 mmoVL tryptophan (Fig 5) . Trolox, a water soluble derivative of vitamin E known to quench both type I and type I1 ROS, could largely substitute for rutin; however, there was no benefit in combining 0.5 mmoVL rutin with 5 mmoVL Trolox. It is interesting that factor VI11 recovery was highest on addition of compounds known to quench both type I and type I1 ROS and less with type I or type I1 quenchers, whether used singly or in combination (Fig 5) .
Electrophoretic analysis of UVC-treated AHF concentrate 
UVC (Jlsq cm)
under denaturing conditions by nonreducing SDS-PAGE and nondenaturing conditions was performed (Fig 6) . Protein banding patterns were better maintained when 0.5 mmoyL rutin was added before exposure to 0.1 J/cm2. In particular, when rutin was not present, two bands migrating slower than the 200,000 MW marker on SDS-PAGE were lost; similarly, on native gels, a band above the 232,000 MW marker became more diffuse. Treatment of plasma. The effects of varying UVC fluency and rutin inclusion on the inactivation of EMCV (Fig  7, left panel) , HAV (Fig 7, right panel) , VSV (Fig 8, left  panel) , and porcine parvovirus (Fig 8, right panel) are provided. At 0.1 J/cm2 UVC, z105.3 TCIDSO of EMCV, z105.3 CFU of HAV, lo6.' TCID50 of VSV, and 2104.5 but <105.8 ID of porcine parvovirus were inactivated. The inclusion of rutin had, at most, a small effect on virus kill. As compared with treatment of a purified AHF concentrate, less factor VI11 was lost on treating plasma with UVC in the absence of exogenously added quenchers (Fig 9) , perhaps because of the presence of endogenous quenchers in plasma. Nonetheless, a benefit of rutin addition on the recovery of several coagulation factors could still be discerned (Fig 9) . At 0.1 J/cm2 UVC irradiation, the electrophoretic banding pattern under nondenaturing or denaturing conditions (SDS) was not affected, even without rutin inclusion (data not shown).
DISCUSSION
The virucidal treatment of plasma and other protein solutions by W C has as its basis the higher absorption of light energies between 250 and 260 nm by nucleic acid as compared with protein and the orders of magnitude larger target presented to W C by the former. The spectrum of nucleic acid modifications include formation of photodimers, photohydrates, and other UVC Treatment of AHF Concentrate at 0.1 J/cm2 SDS Native
adducts?2 Protein damage, where it occurs, principally involves modifications to aromatic amino acids and to disulfide bonds2' Generally, it is easier to inactivate viruses with larger genomes because of their larger target size. In addition, mechanisms of cellular repair are more efficient with double stranded As a result, viruses containing single-stranded DNA or RNA are more sensitive to UVC and single-stranded nucleic acids are also more reactive photochemically than d~uble-stranded.~~ Nonetheless, despite this intrinsic specificity, adoption of W C for the treatment of blood derivatives has been limited, perhaps because of the failure of W C in preventing hepatitis transmission by plasma in the 1 9 5 0~~ and because the recovery of coagulation factors was reduced when fluency was further increased.
In the past IO to 15 years, the viral safety of pooled plasma products has been enhanced greatly, especially with respect to HBV, HCV, and HIV transmission. Nonetheless, nonenveloped viruses, illustrated by HAV and parvovirus B19, have been difficult to eliminate because of their resistance to solvent/detergent or heat treatments and because their small size prevents complete elimination by filtration under conditions that permit passage of large proteins or protein solutions at high concentration (unpublished data). Because HAV and parvovirus have single-stranded genomes, high sensitivity to UVC would be expected." Our results are in accord with this expectation.
The current study demonstrates the enhancement in coagulation factor recovery, with little or no diminution of virus kill, by inclusion of quenchers of ROS. This finding is consistent with the idea that UVC-induced modification of nu- superoxide anion and hydroxy radical) and type I1 ROS (frequently defined as singlet oxygen). Therefore, it is expected that exclusion of oxygen from the system or inclusion of quenchers would have little or no effect on virus inactivation and at the same time protect the plasma proteins. The best results were obtained with rutin, a compound that reacts with both type I and type I1 ROS. For reasons that are unclear, mixtures of quenchers that separately quench type I or type I1 ROS provided less protection against factor VI11 loss. Rutin is a naturally occurring flavonoid commonly found in the parts of plants exposed to sunlight.26 In general, flavonoids are not considered to be toxic, and the daily dietary intake has been estimated at 1 gram per day, with beverages and fruits contributing about 70% of the total." Because of the ingestion and subsequent absorption of large quantities of flavonoids in our daily diet, the choice of flavonoids in general during virus inactivation would appear reasonable from a toxicological perspective. Although rutin at the concentration employed absorbs and, therefore, would be expected to reduce the penetration of UVC into the solution being treated, UVC shielding cannot explain the improved factor VI11 recovery we observed at a given level of virus kill. Moreover, although tryptophan and Trolox each absorb UVC, neither showed the benefit observed with rutin.
Finally, it seems likely that UVC treatment will supplement and not replace current virucidal methods. UVC can most easily be implemented in a manufacturing setting in the treatment of plasma pools or its fractions. While treatment of individual donor units is possible, the requirement for a thin film and for a UVC transparent container render this unlikely. Because the mechanism of UVC inactivation is distinct from the mechanisms of other currently deployed methods, virucidal results with UVC can be added to the results from the other processes. For example, when UVC is combined with solvenudetergent treatment,** the overall clearance of enveloped viruses like HBV and HCV is likely to increase above lolo, and the clearance of HIV is likely to exceed 10". In support of this, we have demonstrated a clearance of 2 l O I 3 IDso of VSV when combining UVC with solvenudetergent. Additionally, UVC also inactivates nonenveloped viruses, especially those with single-stranded genomes like HAV and parvovirus. While more complete stud- Inactivation of VSV and parvovirus in plasma. VSV or porcine parvovirus was added to whole plasma and treated with the indicated dose of UVC. After irradiation, residual virus infectivity was measured as described in Materials and Methods. The results presented ara from a single experiment with each sample diluted serially and each dilution plated in eight replicate tissue culture wells. In subsequent experiments, complete kill of added VSV (results from two experiments; ~1 0~~
TCIDw; 210e,3 TCI D, ) was achieved at 0.07 J/cmz UVC or higher.
In one additional study, complete kill of porcine parvovirus (z~O'.' I&) was achieved at 0.1 J/cmz UVC (0.07 J/cm2 was not studied). Rutin presence had no effect in thesa addiiional studies with VSV and porcine parvovirus.
For personal use only. ies evaluating the structure of UVC-treated proteins are required, including evaluation of neoimmunogens in animals and circulatory recovery and half-life in humans, we conclude that addition of UVC treatment to products that may harbor virus risk will enhance their probability of safety. 
